Live Analyst Rating Changes 37516 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kaveri Pohlman
CS

Kaveri Pohlman

Clear Street
Wall Street Analyst
★★★★☆
#328
on 13Foresight · ranked by our own returns
43%
Success Rate
+3.9%
Average Return
21 of 49 calls profitable · +54.8% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 43% of Kaveri Pohlman's ratings turned a profit when each position was held for 1 year — averaging +3.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

60 Buy 4 Hold 0 Sell
Kaveri's Stock Coverage 36 ratings · 2026-10-05
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
QTTB
Q32 Bio
 Oct 01, 2026 BUY Strong Buy
+575.8% avg upside
28 analysts
$38.00
361.78% Upside
 · ·
SGMT
Sagimet Biosciences, Inc. Class A
 Sep 30, 2026 BUY Strong Buy
+226.9% avg upside
17 analysts
$28.00
206.29% Upside
 · ·
ORKA
Oruka Therapeutics
 Sep 23, 2026 BUY Strong Buy
+60.3% avg upside
16 analysts
$131.00
55.09% Upside
 -5.6% ·
EVMN
Evommune, Inc.
 Sep 09, 2026 BUY Strong Buy
+273.4% avg upside
13 analysts
$23.00
232.31% Upside
 -36.2% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Sep 08, 2026 BUY Strong Buy
+275.6% avg upside
17 analysts
$99.00
257.83% Upside
 -31.5% ·
JBIO
Jade Biosciences
 Sep 04, 2026 BUY Strong Buy
+309.3% avg upside
17 analysts
$48.00
240.03% Upside
 -29.0% ·
PTGX
Protagonist Therapeutics
 Aug 31, 2026 BUY Strong Buy
-14.5% avg upside
19 analysts
$173.00
23.51% Upside
 -4.8% ·
LBRX
LB Pharmaceuticals, Inc.
 Aug 21, 2026 BUY Strong Buy
+49.7% avg upside
9 analysts
$69.00
86.45% Upside
 -22.3% ·
CGEM
Cullinan Management
 Aug 14, 2026 BUY Strong Buy
+126.8% avg upside
16 analysts
$47.00
202.94% Upside
 -21.1% ·
ELVN
Enliven Therapeutics
 Aug 06, 2026 BUY Strong Buy
+32.1% avg upside
18 analysts
$68.00
44.85% Upside
 -22.1% ·
SMMT
Summit Therapeutics
 Aug 03, 2026 BUY Strong Buy
+73.5% avg upside
29 analysts
$31.00
85.05% Upside
 +28.4% ·
EQ
Equillium
 Aug 03, 2026 BUY Strong Buy
+578.4% avg upside
16 analysts
$9.00
538.38% Upside
 -35.9% ·
MLTX
MoonLake Immunotherapeutics
 Jun 22, 2026 BUY Strong Buy
+167.2% avg upside
20 analysts
$70.00
513.53% Upside
 -48.5% ·
TRVI
Trevi Therapeutics
 May 07, 2026 BUY Strong Buy
+72.2% avg upside
18 analysts
$29.00
108.42% Upside
 -1.0% ·
MDGL
Madrigal Pharmaceuticals
 May 06, 2026 BUY Strong Buy
+3.5% avg upside
34 analysts
$680.00
36.22% Upside
 -7.4% ·
PALI
Palisade Bio
 Mar 31, 2026 BUY Strong Buy
+1690.8% avg upside
16 analysts
$12.00
733.32% Upside
 -20.9% ·
ERAS
Erasca
 Mar 06, 2026 BUY Strong Buy
+44.1% avg upside
14 analysts
$20.00
35.68% Upside
 -4.7% ·
PVLA
Palvella Therapeutics
 Mar 02, 2026 BUY Strong Buy
+27.5% avg upside
27 analysts
$220.00
66.08% Upside
 +4.0% ·
JANX
Janux Therapeutics Inc
 Jan 20, 2026 HOLD Strong Buy
+168.4% avg upside
22 analysts
$12.00
29.03% Downside
 +28.7% ·
IMTX
Immatics
 Dec 11, 2025 BUY Strong Buy
+138.7% avg upside
15 analysts
$18.00
137.06% Upside
 -15.9% ·
ZURA
Zura Bio
 Dec 01, 2025 BUY Strong Buy
+288.5% avg upside
13 analysts
$18.00
338.05% Upside
 +7.5% ·
NUVB
Nuvation Bio
 Nov 26, 2025 BUY Strong Buy
+159.9% avg upside
18 analysts
$12.00
133.53% Upside
 -35.8% ·
AVBP
ArriVent BioPharma, Inc.
 Nov 11, 2025 BUY Strong Buy
+53.8% avg upside
15 analysts
$47.00
66.30% Upside
 +45.9% ·
RCUS
Arcus Biosciences
 Nov 29, 2024 HOLD Strong Buy
+45.5% avg upside
21 analysts
 — +69.0% ·
XNCR
Xencor
 Nov 29, 2024 HOLD Strong Buy
+42.8% avg upside
27 analysts
 — -32.3% ·
MGNX
MacroGenics
 Nov 29, 2024 HOLD Buy
+394.0% avg upside
25 analysts
 — -57.4% ·
EXEL
Exelixis
 Nov 29, 2024 HOLD Buy
-27.5% avg upside
34 analysts
 — +21.1% ·
PYXS
Pyxis Oncology
 Nov 29, 2024 HOLD Strong Buy
+277.3% avg upside
15 analysts
 — +158.2% ·
STTK
Shattuck Labs
 Nov 29, 2024 HOLD Strong Buy
+223.1% avg upside
16 analysts
 — +90.9% ·
REPL
Replimune Group
 Nov 29, 2024 HOLD Strong Buy
+76.9% avg upside
14 analysts
 — -29.0% ·
GMAB
Genmab
 Nov 29, 2024 HOLD Strong Buy
+81.5% avg upside
27 analysts
 — +50.5% ·
BCAB
BioAtla
 Jun 02, 2024 BUY Strong Buy
+7201.4% avg upside
13 analysts
$13.00
892.32% Upside
 · ·
INMB
Inmune Bio
 Apr 29, 2024 BUY Buy
+540.9% avg upside
11 analysts
$21.00
988.14% Upside
 -33.3% ·
NEXI
NexImmune
 Sep 01, 2023 HOLD Buy
+7499900.0% avg upside
4 analysts
 — · ·
ONCSQ
OncoSec Medical
 Nov 23, 2022 HOLD Strong Buy
+4699999900.0% avg upside
9 analysts
 — · ·
CTMX
CytomX Therapeutics
 Jul 06, 2022 BUY Strong Buy
+321.7% avg upside
21 analysts
$8.00
212.45% Upside
 -8.1% ·
🔒 31 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kaveri Pohlman — Frequently Asked Questions
How accurate are Kaveri Pohlman's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Kaveri's ratings were profitable over a one-year hold, with an average return of +3.9% per rating, or +54.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kaveri ranked on 13Foresight?
Kaveri Pohlman is currently ranked #328 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kaveri cover?
Kaveri most recently has ratings on QTTB, SGMT, ORKA, EVMN, GPCR, JBIO, PTGX, LBRX, CGEM, ELVN, SMMT, EQ and 24 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.